Dual-targeted drug delivery system based on dopamine functionalized human serum albumin nanoparticles as a carrier for methyltestosterone drug

Document Type : Research Paper


1 Department of Applied Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran

2 Faculty of Chemistry, Sensor and Biosensor Research Center (SBRC) & Nanoscience and Nanotechnology Research Center (NNRC), Razi University, Kermanshah, Iran

3 Nano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

4 Department of Chemistry, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran

5 Medical Biology Research Center (MBRC), Kermanshah University of Medical Sciences, Kermanshah, Iran


Objective(s): This study aims to enhance 17 a-methyltestosterone loaded human serum albumin nanoparticles (MT-HSA NPs) bioavailability through a desolvation technique. Dopamine (DA) molecules were conjugated on the surface of MT-HSA NPs and have the potential to act as tiny proper ligands in a unique treatment system to cope with cancer in which drug will be transmitted to the cancer area. Herein, we used HSA as an adaptable carrier of anticancer agents for methyltestosterone transport to the tumor site via DA D1-D5 receptors. In the present study, sonication of MT-HSA solution was carried out before the desolvation procedure to increase the drug loading and entrapment efficiency.
Materials and Methods: Various parameters were optimized to characterize NPs including morphology, size, zeta potential, polydispersity index, drug release profile, and entrapment efficiency.
Results: Under the optimum conditions of HSA and drug (1:41), at pH 9, results demonstrate sizes of 69 nm and 82 nm for MT-HSA and MT-HSA-DA NPs respectively. For MT-HSA NPs, the polydispersity index was found to be 0.3 and the average drug loading and encapsulation efficiency were 14% and 91% respectively. Anticancer activity and the release of drug was investigated through MCF-7 breast cancer cell line. Results show that targeted NPs are more effective than non-targeted NPs.
Conclusion: According to these studies, the therapeutic effects against various diseases such as cancers increase through cellular targeting property of a biocompatible drug delivery system. This is the first report for methyltestosterone delivery to breast cancer cells based on HSA NPs.


1.Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy. Signal transduct target ther. 2018; 3 (1): 7.
2.Norouzi P, amini M, Mottaghitalab F, Mirzazadeh Tekie FS, Dinarvand R, Mirzaie ZH, Atyabi F. Design and fabrication of dual‐targeted delivery system based on gemcitabine conjugated human serum albumin nanoparticles. Chem Biol Drug Des. 2017.
3.Kouchakzadeh H, Shojaosadati SA, Shokri F. Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chem Eng Res Des. 2014; 92 (9): 1681-1692.
4.Chida T, Miura Y, Cabral H, Nomoto T, Kataoka K, Nishiyama N. Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release. J Control Release. 2018; 292: 130-140.
5.Zununi Vahed S, Salehi R, Davaran S, Sharifi S. Corrigendum to” Liposome-based drug co-delivery systems in cancer cells” (Mater. Sci. Eng.(2017) C 71 (1327-1341)(S0928493116322871)(10.1016/j. msec. 2016.11. 073)). Mater Sci Eng C. 2018; 83: 247.
6.Xiong Z, Shen M, Shi X. Dendrimer-based strategies for cancer therapy: Recent advances and future perspectives. Sci China Mater. 2018; 61(11): 1387-1403.
7.Lim E-K, Chung BH, Chung SJ. Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy. Curr Drug Targets. 2018; 19(4): 300-317.
8.Yu X, Trase I, Ren M, Duval K, Guo X, Chen Z. Design of nanoparticle-based carriers for targeted drug delivery. J Nanomater. 2016; 2016.
9.Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012; 161(1): 38-49.
10.Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Medchemcomm. 2019.
11.Dockal M, Carter DC, Rüker F. The three recombinant domains of human serum albumin structural characterization and ligand binding properties. J Biol Chem. 1999; 274(41): 29303-29310.
12.Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, Shahreza S, Sori M, Hamblin MR. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016; 13(11): 1609-1623.
13.Lomis N, Westfall S, Farahdel L, Malhotra M, Shum-Tim D, Prakash S. Human serum albumin nanoparticles for use in cancer drug delivery: process optimization and in vitro characterization. Nanomaterials. 2016; 6(6): 116.
14.Niknejad H, Mahmoudzadeh R. Comparison of different crosslinking methods for preparation of docetaxel-loaded albumin nanoparticles. Iran J Pharm Res. 2015; 14 (2): 385.
15.Taneja N, Singh KK. Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan. Int J Pharm. 2018; 536(1): 82-94.
16.Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132(3): 171-183.
17.Zhao S, Wang W, Huang Y, Fu Y, Cheng Y. Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds. Medchemcomm. 2014; 5(11): 1658-1663.
18.Saleh T, Soudi T, Shojaosadati SA. Redox responsive curcumin-loaded human serum albumin nanoparticles: Preparation, characterization and in vitro evaluation. Int J Biol Macromol. 2018; 114: 759-766.
19.Nateghian N, Goodarzi N, Amini M, Atyabi F, Khorramizadeh MR, Dinarvand R. Biotin/folate‐decorated human serum albumin nanoparticles of docetaxel: comparison of chemically conjugated nanostructures and physically loaded nanoparticles for targeting of breast cancer. Chem Biol Drug Des. 2016; 87(1): 69-82.
20.Kouchakzadeh H, Hoseini Makarem S, Shojaosadati S. Simultaneous loading of 5-florouracil and SPIONs in HSA nanoparticles: Optimization of preparation, characterization and in vitro drug release study. Nanomed J. 2016; 3(1): 35-42.
21.Masoudipour E, Kashanian S, Maleki N. A targeted drug delivery system based on dopamine functionalized nano graphene oxide. Chem Phys Lett. 2017; 668: 56-63.
22.Das P, Jana NR. Dopamine functionalized polymeric nanoparticle for targeted drug delivery. RSC Adv. 2015; 5(42): 33586-33594.
23.Borcherding DC, Tong W, Hugo ER, Barnard DF, Fox S, LaSance K, Shaughnessy E, Ben-Jonathan N. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene. 2016; 35(24): 3103.
24.Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol. 2017; 11(5): 87.
25.Mor G, Eliza M, Song J, Wiita B, Chen S, Naftolin F. 17α-Methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J Steroid Biochem Mol Biol. 2001; 79(1-5): 239-246.
26.Kamali M, Dinarvand R, Maleki H, Arzani H, Mahdaviani P, Nekounam H, Adabi M, Khosravani M. Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma. RSC Adv. 2015; 5(76): 62214-62219.
27.Jahanban-Esfahlan A, Dastmalchi S, Davaran S. A simple improved desolvation method for the rapid preparation of albumin nanoparticles. Int J Biol Macromol. 2016; 91: 703-709.
28.Agarwal A, Lvov Y, Sawant R, Torchilin V. Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. J Control Release. 2008; 128(3) 255-260.
29.Kimura K, Yamasaki K, Nakamura H, Haratake M, Taguchi K, Otagiri M. Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives. Chem Pharm Bull. 2018; 66(4): 382390-.
30.Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. International journal of nanomedicine Int J Nanomedicine.2010; 525: 5.
31.Kim S, Jang Y, Jang LK, Sunwoo SH, Kim T-i, Cho S-W, Lee JY. Electrochemical deposition of dopamine–hyaluronic acid conjugates for anti-biofouling bioelectrodes. J Mater Chem B. 2017; 5(23): 4507-4513.
32.Taneja N. Preparation of size controlled albumin nanoparticles and its in- vitro safety evaluation. Eur J Pharm Med Res. 2017; 4 (07): 478-484.
33.Mehravar R, Jahanshahi M, Saghatoleslami N. Human serum albumin (HSA) nanoparticles as drug delivery system: preparation, optimization and characterization study. Dyn Biochem Process Biotechnol Mol Biol. 2009; 3: 51-56.
34.Guo H, Fei S, Zhang Y, Zhang Y, Gou J, Zhang L, He H, Yin T, Wang Y, Tang X. Teniposide-loaded multilayer modified albumin nanoparticles with increased passive delivery to the lung. RSC Adv. 2016; 6 (84): 81110-81119.
35.Tao X, Jin S, Wu D, Ling K, Yuan L, Lin P, Xie Y, Yang X. Effects of particle hydrophobicity, surface charge, media pH value and complexation with human serum albumin on drug release behavior of mitoxantrone-loaded pullulan nanoparticles. Nanomaterials. 2016; 6 (1): 2.
36.Sun Y, Zhao Y, Teng S, Hao F, Zhang H, Meng F, Zhao X, Zheng X, Bi Y, Yao Y. Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. Int J Nanomedicine. 2019; 14: 135.
37.Keum C-G, Noh Y-W, Baek J-S, Lim J-H, Hwang C-J, Na Y-G, Shin S-C, Cho C-W. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid. Int J Nanomedicine. 2011; 6: 2225.
38.Hawe A, Friess W. Stabilization of a hydrophobic recombinant cytokine by human serum albumin. J Pharm Sci. 2007; 96 (11): 2987-2999.
39.Ghosh P, Roy AS, Chaudhury S, Jana SK, Chaudhury K, Dasgupta S. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity. Int J Biol Macromol. 2016; 86: 408-417.
40.Mohammad-Beigi H, Shojaosadati SA, Morshedi D, Mirzazadeh N, Arpanaei A. The effects of organic solvents on the physicochemical properties of human serum albumin nanoparticles. Iran J Biotechnol. 2016; 14 (1): 45.
41.Ahsan SM, Rao CM. The role of surface charge in the desolvation process of gelatin: implications in nanoparticle synthesis and modulation of drug release. Int J Nanomedicine. 2017; 12: 795.
42.Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 2003; 257 (1-2): 169-180.
43.Choi J-S, Meghani N. Impact of surface modification in BSA nanoparticles for uptake in cancer cells. Colloids Surf B Biointerfaces. 2016; 145: 653-661.
44.Sivasankar M, Kumar BP. Role of nanoparticles in drug delivery system. Int. J. Pharm. Biomed. Res. 2010; 1 (2): 41-66.
45.Qu N, Sun Y, Li Y, Hao F, Qiu P, Teng L, Xie J, Gao Y. Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation. Biomedical engineering online. Biomed. Eng. Online. 2019; 18 (1): 11.
46.Boateng-Marfo Y, Dong Y, Loh ZH, Lin H, Ng WK. Intravenous human serum albumin (HSA)-bound artemether nanoparticles for treatment of severe malaria. Colloids Surf. A Physicochem. Eng. Asp. 2018; 536: 20-29.
47.Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, Kore G, Misra A. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J Drug Deliv Sci Technol. 2018; 45: 334-345.